# What HCPs say could reveal prescribing intent

- Link: https://www.directorstalkinterviews.com/what-hcps-say-could-reveal-prescribing-intent/4121265678
- Published: 2026-10-09T11:02:00+01:00
- Author: Amilia Stone

Talking Medicines is targeting a specific problem for pharmaceutical companies, 
understanding what actually influences healthcare professionals before they decide
whether to prescribe a medicine.

Pharmaceutical marketing teams typically track reach, impressions, clicks and engagement
to measure the impact of campaigns. These figures show whether HCPs have seen or
interacted with content, but they do not necessarily explain why a doctor may consider,
reject or continue using a particular treatment.

Talking Medicines says prescribing intent is influenced by several factors, including
clinical evidence, treatment experience, tolerability, contraindications, administration,
monitoring requirements, treatment alternatives and local guidelines. Patient requests
and discussions with pharmaceutical representatives can also influence how medicines
are considered.

This creates a gap between marketing activity and prescribing intent. A campaign
can generate strong engagement without addressing the questions or concerns that
are affecting treatment decisions.

The company is using analysis of HCP conversations to address that gap. Its DrugVoice
platform analyses unstructured conversations using artificial intelligence, natural
language processing and healthcare-specific data science.

Rather than simply measuring how frequently a medicine is mentioned, the platform
looks at what HCPs are saying about it. This can include discussions around clinical
evidence, treatment experience, tolerability, differentiation, patient suitability
and unmet needs.

For pharmaceutical companies, this information can provide a clearer view of the
issues influencing treatment consideration. It can also show whether the messages
being delivered through marketing campaigns reflect the issues HCPs are discussing
in practice.

The distinction between exposure and intent is significant. Two medicines could 
receive similar levels of marketing engagement while generating very different conversations
among HCPs. One may be discussed positively in relation to a particular patient 
group, while another may attract questions about tolerability or differentiation.

Talking Medicines is therefore focused on turning conversations that would otherwise
remain unstructured into information that pharmaceutical companies can analyse.

_**[Tern plc](https://www.directorstalkinterviews.com/company/tern-plc/tern.l) **(
[LON:TERN](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)) backs
exciting, high growth IoT innovators in Europe. They provide support and create 
a genuinely collaborative environment for talented, well-motivated teams._

Share on:
